北京若生智能科技有限公司
Drug Database
TR

travoprost + timolol (TTFC, Alcon / TTFC, Alcon)

✓ Approved

Novartis AG · ADRB1 · 小分子

什么是 travoprost + timolol？

travoprost + timolol 是一种小分子，由Novartis AG研发。该药已获批，用于治疗相关适应症，给药途径：Others。

药物档案

商品名TTFC, Alcon, TTFC, Alcon
公司Novartis AG
药物类别小分子
分子靶点ADRB1, ADRB2, PTGFR
给药途径Others
状态Approved
来源： ClinicalTrials.gov, Novartis AG

作用机制

分子靶点

travoprost + timolol 作用于 3 个分子靶点：

ADRB1adrenoceptor beta 1 (B1AR, RHR)
ADRB2adrenoceptor beta 2 (ADRBR, B2AR)
PTGFRprostaglandin F receptor (FP)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

travoprost + timolol 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Eye disordersGlaucoma✓ Approved

相关研究文献

PubMedIndian dermatology online journal2026-10-26

In Vivo Study of Topical Bimatoprost, Latanoprost, Travoprost in Comparison with Minoxidil on Hair Growth in C57BL/6 Mice.

Navale Vrushali Shankar VS, Marathe Padmaja Anil PA, Patil Sharmila P SP

Alopecia significantly affects psychological well-being and social functioning. Standard treatments, like minoxidil and finasteride, are limited by delayed efficacy, need for lifelong use, and adverse effects. Prostaglandin analogs (PGAs), originally developed for ocular hypertension, have shown promise in promoting hair growth. This study compares their effects with minoxidil in a murine model. To compare the effects of bimatoprost, latanoprost, and travoprost on hair growth in C57BL/6 mice, with evaluation of hair density, follicle diameter, and growth rate using minoxidil as the comparator. After Institutional Animal Ethics Committee approval, 40 male C57BL/6 mice (aged 6-7 weeks, weighing 20-25 g) were randomized into five groups ( n = 8 in each group): (1) vehicle control, (2) minoxidil 5%, (3) latanoprost 0.005%, (4) bimatoprost 0.03%, and (5) travoprost 0.004%. Drugs were applied topically to shaved dorsal skin daily for 28 days. Hair growth was assessed by follicle density, bulb diameter, and area of regrowth using ImageJ from photographs taken on days 1, 7, 15, and 28. All PGAs significantly increased hair density compared to vehicle control (vehicle control: 1.50 ± 0.55 vs. latanoprost: 7.50 ± 1.69, bimatoprost: 7.75 ± 2.87, travoprost: 6.87 ± 3.40; P = 0.001). Latanoprost and bimatoprost showed higher hair density than minoxidil (3.75 ± 2.87; P = 0.038 and 0.010, respectively). Hair follicle diameter was greater with PGAs (latanoprost: 53.12 ± 5.30, bimatoprost: 51.87 ± 7.52, travoprost: 48.12 ± 3.47 μm) versus vehicle control (27.91 ± 5.57 μm, P = 0.001) and minoxidil (38.12 ± 5.46 μm, P = 0.001). Bimatoprost showed the greatest regrowth by day 28, while latanoprost demonstrated earlier onset by day 15. PGAs also caused darker pigmentation and longer hair. The present study duration was limited to 4 weeks. Minoxidil (positive control) did not show noticeable hair growth because its effects usually take 6-8 weeks to appear. Topical PGAs improved key hair growth parameters. Bimatoprost and latanoprost showed early and superior efficacy by day 28.

PMID 42929802
阅读全文 →
PubMedAmerican journal of ophthalmology case reports2026-10-25

Recurrent delayed hyphema following latanoprost/netarsudil initiation in an eye with a XEN 63 gel stent: a case report.

Greco Antonio A, Calabresi Valerio V, Marenco Maria M, Garavelli Fabio F et al.

To describe recurrent delayed hyphema following initiation of fixed-dose latanoprost/netarsudil in an eye with a previous XEN 63 gel stent, and to discuss whether the associated IOP reduction may have unmasked a pre-existing peri-implant reflux pathway. A 72-year-old woman with advanced primary open-angle glaucoma and previous ab interno XEN 63 gel stent implantation developed recurrent spontaneous hyphema shortly after bimatoprost/timolol was replaced with latanoprost/netarsudil. Intraocular pressure decreased from 17-19 mmHg to 8-9 mmHg after treatment initiation. The first episode occurred nine days later, with blurred vision, a small anterior chamber hyphema, and fine endothelial blood deposits. Gonioscopy showed active blood reflux from tissue surrounding the proximal intracameral XEN segment, without bleeding from other angle structures. Recurrent episodes occurred despite conservative management and, subsequently, despite discontinuation of latanoprost/netarsudil. Because the peri-implant region was repeatedly identified as the reflux site, the XEN stent was eventually removed. No further bleeding episodes were observed after explantation. The clinical course is consistent with a susceptible peri-implant anatomical configuration contributing to recurrent blood reflux. The temporal association between latanoprost/netarsudil initiation, marked IOP reduction, and the first hyphema suggests a possible precipitating or unmasking role, but does not establish drug causality. Delayed or recurrent hyphema after XEN implantation should prompt review of recent medication changes and careful gonioscopic inspection of the proximal XEN segment.

PMID 42927338
阅读全文 →
PubMedActa ophthalmologica2026-10-24

Therapeutic efficacy and systemic pharmacokinetics of a dual-drug hydrogel contact lens for sustained glaucoma therapy.

Varshitha Vangol V, Sankararajan Umadevi U

Conventional topical therapy for glaucoma is limited by poor ocular bioavailability, rapid precorneal drug loss, frequent dosing and systemic absorption through the nasolacrimal pathway, which may reduce therapeutic efficacy and increase the risk of adverse effects. Drug-eluting hydrogel contact lenses have emerged as a promising strategy to overcome these limitations by enabling sustained ocular drug delivery. This study aimed to evaluate the therapeutic efficacy, ocular biocompatibility and systemic pharmacokinetic profile of an optimized dual-drug-loaded HEMA-based hydrogel contact lens delivering timolol maleate (TM) and brimonidine tartrate (BT) for sustained glaucoma management. Optimized hydrogel contact lenses composed of 2-hydroxyethyl methacrylate (HEMA), N, N-dimethylacrylamide (DMA), N-vinylpyrrolidone (NVP) and ethylene glycol dimethacrylate (EGDMA) were fabricated by UV photopolymerization and loaded with TM and BT (4 mg/mL each). Ocular biocompatibility was assessed using the modified Draize irritation test. Therapeutic efficacy was evaluated in a steroid-induced ocular hypertension New Zealand White rabbit model by monitoring intraocular pressure (IOP) for 24 h. Systemic drug exposure was determined by validated high-performance liquid chromatography (HPLC) analysis of plasma samples, while ocular safety was further confirmed through histopathological examination. The optimized hydrogel lens exhibited excellent ocular biocompatibility, with a maximum Draize score of 0.33 ± 0.12 that resolved completely within 48 h and no histopathological evidence of ocular tissue damage. In hypertensive rabbits, the dual-drug hydrogel lens maintained normotensive IOP (16.1 ± 0.8 mmHg) for 24 h, representing a 43.5% reduction from baseline and significantly outperforming conventional eye drops beyond 4 h (p < 0.01). Plasma concentrations of both TM and BT remained below the limit of quantification (<2.0 ng/mL) throughout the study, whereas conventional eye drops produced measurable systemic exposure (TM: 18.4 ± 2.1 ng/mL; BT: 8.2 ± 1.2 ng/mL), demonstrating effective minimization of systemic drug absorption. The optimized dual-drug-loaded hydrogel contact lens provided sustained intraocular pressure reduction, excellent ocular biocompatibility and negligible systemic drug exposure compared with conventional topical therapy. These findings highlight its potential as a sustained ocular drug-delivery platform capable of improving therapeutic efficacy, reducing systemic adverse effects and enhancing long-term treatment adherence in glaucoma management. Further long-term preclinical investigations and clinical studies are warranted to support clinical translation.

PMID 42920388
阅读全文 →
PubMedCutaneous and ocular toxicology2026-10-20

Ex vivo evaluation of corneal permeation and irritation potential associated with proparacaine hydrochloride misuse.

Gonzalez-Jimenez Natalia C NC, Lozano María C MC, Baena Yolima Y

Proparacaine hydrochloride is a topical ocular anesthetic widely used in diagnostic procedures. Although generally safe when properly administered, repeated or unsupervised use has been associated with clinically relevant corneal injury. In contexts where access to topical anesthetics is insufficiently controlled, misuse may result in cumulative epithelial damage and vision-threatening complications. Despite clinical reports and experimental evidence of corneal toxicity, quantitative data linking exposure conditions to structural corneal damage under controlled ex vivo settings remain limited, particularly regarding dose-injury relationships at the tissue level. Porcine corneas were mounted in Franz diffusion cells to quantify permeation by UV-Vis spectrophotometry and evaluate corneal histopathological changes. Both pure proparacaine and the commercial 0.5% proparacaine hydrochloride ophthalmic solution (Alcaine®, Alcon) were assessed under therapeutic (2.25 mg/mL), abuse (4.5 mg/mL), and infinite-dose (53.152 mg/mL) conditions. Negative (phosphate-buffered saline) and positive (99.5% ethanol) controls were included for histopathological assessment. ANOVA was applied to permeation data, and histopathological scores were analyzed using non-parametric tests. Proparacaine showed low permeability (9.33 × 10-7 cm/s), with only a small fraction of the applied dose permeating across the cornea during the experimental period. Permeation increased in a concentration- and time-dependent manner. High-dose and infinite-dose exposure conditions resulted in marked epithelial damage, including spongiosis, chromatin condensation, and desquamation, with severity comparable to that induced by ethanol used as a positive control. Differences between formulations were primarily driven by concentration rather than formulation composition, and a correlation was observed between cumulative permeation and the extent of epithelial injury. Proparacaine demonstrates dose-dependent permeation and histopathological changes, emphasizing the risks associated with misuse. The ex vivo model provides relevant and ethically aligned evidence to support ocular hazard assessment through the characterizing of histopathological changes.

PMID 42900757
阅读全文 →
PubMedInternational ophthalmology2026-10-15

Comparative safety and complication profiles of two three-piece intraocular lenses in Yamane technique.

Karadağ Erdi E, Akçay Güzide G, Tanyıldız Burak B, Kıvrak Ulviye U et al.

To compare the mechanical behavior, intraoperative events, and postoperative outcomes of two three-piece intraocular lenses (IOLs) with different haptic materials-polymethyl methacrylate (PMMA) and polyvinylidene fluoride (PVDF)-implanted using the Yamane fixation technique. This retrospective comparative study included eyes undergoing Yamane scleral fixation with either a PMMA-haptic IOL (Alcon MA60AC) or a PVDF-haptic IOL (Eyecryl Plus TP613). Preoperative and postoperative month 6 best-corrected visual acuity (BCVA), intraocular pressure (IOP), and cylindrical refraction, as well as intraoperative haptic-related complications including haptic tip breakage and optic-haptic junction separation, postoperative IOL dislocation, and other postoperative complications were recorded and analyzed. Seventy-four eyes (37 per group) were included. Baseline demographic and preoperative clinical characteristics were similar between groups. At 6 months, BCVA improved significantly in both groups without a significant intergroup difference, and postoperative IOP values and cylindrical refraction were comparable. Intraoperative complications were more frequent in the Alcon group (32.4%, 95% CI 19.6-48.5% vs. 5.4%, 95% CI 1.5-17.7%; p = 0.003), with haptic-related complications occurring exclusively in this group. Overall postoperative complication rates were similar; however, IOL dislocation occurred only in the Alcon group (16.2%, 95% CI 7.7-31.1% vs. 0%; p = 0.025). Other postoperative complications did not differ significantly. Both IOLs yielded comparable improvements in visual acuity; however, all haptic-related complications and IOL dislocations occurred exclusively in the Alcon MA60AC group. These findings suggest that IOL selection is an important consideration in Yamane fixation, and the Eyecryl Plus TP613 with its PVDF haptics and more favorable design profile may offer greater biomechanical reliability.

PMID 42878917
阅读全文 →
PubMedJournal of the Chinese Medical Association : JCMA2026-10-14

Nonselective beta-blockers and hepatic encephalopathy in liver cirrhosis:A meta-analysis of randomized controlled trials.

Kuo Tai-Hui TH, Chen Yu-Jen YJ, Lee Pei-Chang PC, Yang Tsung-Chieh TC et al.

Liver cirrhosis leads to portal hypertension and related complications, including ascites, esophageal varices, and hepatic encephalopathy (HE). Non-selective beta blockers (NSBBs) decrease portal pressure, but it is not yet clear whether they contribute to HE development. Therefore, we examined the association between NSBB therapy and HE in randomized controlled trials (RCTs) involving patients with cirrhosis. We systematically searched PubMed, Web of Science, ScienceDirect, and the Cochrane Library (from inception to December 31, 2024) for RCTs comparing NSBBs with a placebo, endoscopic band ligation, or injection sclerotherapy for variceal bleeding prevention in relation to HE. The risk ratios (RRs) and 95% confidence intervals (CIs) were pooled using a random-effects model. Subgroups were defined according to the comparator, NSBB type, and hepatic function status (weighted mean Child-Pugh score ≤6 vs. >6). The risk of bias was assessed using the revised Cochrane risk-of-bias tool for randomized trials (RoB 2). There were 12 relevant studies, which included 775 NSBB-treated and 771 comparator patients (54 and 57 HE events). NSBB therapy was not associated with a statistically significant change in HE risk (RR 1.04, 95% CI 0.73-1.47; p = 0.84; I² = 0%). Estimates were consistent across all subgroups of hepatic function statuses (compensation, RR 1.18, 0.44-3.14; decompensation, RR 1.02, 0.70-1.48; p = 0.79), comparators (placebo, RR 1.19, 0.79-1.80; endoscopic therapy, RR 0.72, 0.38-1.39; p = 0.20), and NSBB types (propranolol/timolol, RR 1.06, 0.72-1.55; carvedilol, RR 0.95, 0.42-2.15; p = 0.82). Current evidence does not indicate a statistically significant association between NSBB therapy and HE development in patients with cirrhosis, regardless of disease severity.

PMID 42870342
阅读全文 →

注册免费账户还可查看另外 7359 篇文献

免费注册查看全部文献 →

了解更多travoprost + timolol